MPO: Difference between revisions
From haematologyetc.co.uk
(Created page with " <div style="background-color: #E0EEEE; {{round corners}} padding: 2em 2em; margin-right: 5px;"> :<span style="color:navy">'''Summary'''</span> :xxxx </div> <span style="color:navy">'''Normal expression and function'''</span> xxxxx <span style="color:navy">'''Diagnostic role'''</span> *xxxxx <span style="color:navy">'''Other relevant information:'''</span> xxxxx ---- <span style="color:navy">'''''SUMMARY TABLES'''''</span> <span style="font-...") |
No edit summary |
||
| Line 5: | Line 5: | ||
:<span style="color:navy">'''Summary'''</span> | :<span style="color:navy">'''Summary'''</span> | ||
: | :MPO expression is strongly associated with granulocytic maturation. In acute leukaemia MPO has high specificity for the diagnosis of AML, although expression may be observed on more primitive AML, or where maturation is non-granulocytic e.g. erythroid or megakaryocyte lineages and on some monocytic cases. Expression is not observed in typical ALL, if MPO is detected in ALL then this supports the diagnosis of mixed-phenotype acute leukaemia (MPAL). | ||
Revision as of 09:43, 31 May 2023
- Summary
- MPO expression is strongly associated with granulocytic maturation. In acute leukaemia MPO has high specificity for the diagnosis of AML, although expression may be observed on more primitive AML, or where maturation is non-granulocytic e.g. erythroid or megakaryocyte lineages and on some monocytic cases. Expression is not observed in typical ALL, if MPO is detected in ALL then this supports the diagnosis of mixed-phenotype acute leukaemia (MPAL).
Normal expression and function
xxxxx
Diagnostic role
- xxxxx
Other relevant information:
xxxxx
SUMMARY TABLES
Note The colour and % refer to the proportion of cases expressing the marker. Additional comments on strength, or site of expression (if relevant) are given below the table. For full details of key click here. For further information about a particular disease state click <I> adjacent to the condition name
| Expression in primitive cell types | |||||||
|---|---|---|---|---|---|---|---|
| AML | CMML | B ALL | Burkitt | T ALL | ETP ALL <I> | MPAL <I> | Hgns <I> |
| ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% |
Notes: xxxxx
| Expression in mature B cell neoplasms | |||||||
|---|---|---|---|---|---|---|---|
| CLL | MCL | FL | MZL | HCL | DLBCL | LPL | PCL |
| ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% |
Notes: xxxxx
| Expression in mature T cell neoplasms* | ||||||
|---|---|---|---|---|---|---|
| ATLL | CTCL/Sezary | T-PLL | T-LGL | NK-LGL | ||
| ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ||
Notes: xxxxx